These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

722 related articles for article (PubMed ID: 34635626)

  • 1. Metabolic Dysfunction-Associated Fatty Liver Disease Predicts Long-term Mortality and Cardiovascular Disease.
    Moon JH; Kim W; Koo BK; Cho NH;
    Gut Liver; 2022 May; 16(3):433-442. PubMed ID: 34635626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of all-cause mortality associated with non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease in Taiwan MJ cohort.
    Cheng WC; Chen HF; Cheng HC; Li CY
    Epidemiol Health; 2024; 46():e2024024. PubMed ID: 38317531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study.
    Wang X; Wu S; Yuan X; Chen S; Fu Q; Sun Y; Lan Y; Hu S; Wang Y; Lu Y; Qu S; Wang L
    J Clin Endocrinol Metab; 2022 Jan; 107(2):e745-e755. PubMed ID: 34467980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan.
    Yoneda M; Yamamoto T; Honda Y; Imajo K; Ogawa Y; Kessoku T; Kobayashi T; Nogami A; Higurashi T; Kato S; Hosono K; Saito S; Nakajima A
    J Gastroenterol; 2021 Nov; 56(11):1022-1032. PubMed ID: 34601620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic Dysfunction-Associated Fatty Liver Disease and Mortality: A Population-Based Cohort Study.
    Kim KS; Hong S; Ahn HY; Park CY
    Diabetes Metab J; 2023 Mar; 47(2):220-231. PubMed ID: 36631994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non-alcoholic fatty liver disease.
    Chun HS; Lee M; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Lee YH; Kim JH; Kim SU
    Liver Int; 2023 Mar; 43(3):608-625. PubMed ID: 36585250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Stroke With Metabolic Dysfunction-Associated Fatty Liver Disease With and Without CKD.
    Li Y; Wu S; Gao J; Zhang Y; Zuo Y; Tian X; Chen S; Xing A; Wang A; He Y
    Am J Kidney Dis; 2024 Apr; 83(4):477-488. PubMed ID: 37838141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of metabolic factors on risk of cardiovascular disease in nondiabetic metabolic dysfunction-associated fatty liver disease.
    Kang MK; Lee YR; Jang SY; Tak WY; Kweon YO; Song JE; Loomba R; Park SY; Park JG
    Hepatol Int; 2023 Jun; 17(3):626-635. PubMed ID: 37069419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic dysfunction-associated fatty liver disease and liver function markers are associated with Crohn's disease but not Ulcerative Colitis: a prospective cohort study.
    Chen J; Dan L; Tu X; Sun Y; Deng M; Chen X; Hesketh T; Li R; Wang X; Li X
    Hepatol Int; 2023 Feb; 17(1):202-214. PubMed ID: 36194337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new risk stratification strategy for fatty liver disease by incorporating MAFLD and fibrosis score in a large US population.
    Zhang YC; Lyu ZY; Ma B; Li LM; Wang W; Sheng C; Dai HJ; Huang YB; Song FF; Song FJ; Chen KX
    Hepatol Int; 2022 Aug; 16(4):835-845. PubMed ID: 35701716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic dysfunction-associated fatty liver disease predicts new onset of chronic kidney disease better than fatty liver or nonalcoholic fatty liver disease.
    Tanaka M; Mori K; Takahashi S; Higashiura Y; Ohnishi H; Hanawa N; Furuhashi M
    Nephrol Dial Transplant; 2023 Feb; 38(3):700-711. PubMed ID: 35612975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States.
    Kim D; Konyn P; Sandhu KK; Dennis BB; Cheung AC; Ahmed A
    J Hepatol; 2021 Dec; 75(6):1284-1291. PubMed ID: 34380057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic Dysfunction-Associated Fatty Liver Disease Is Associated with the Risk of Incident Cardiovascular Disease: A Prospective Cohort Study in Xinjiang.
    Guo Y; Yang J; Ma R; Zhang X; Guo H; He J; Wang X; Cao B; Maimaitijiang R; Li Y; Peng X; Zhang S; Guo S
    Nutrients; 2022 Jun; 14(12):. PubMed ID: 35745091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of concomitant hepatitis C virus infection on liver and cardiovascular risks in patients with metabolic-associated fatty liver disease.
    Tsai PS; Cheng YM; Wang CC; Kao JH
    Eur J Gastroenterol Hepatol; 2023 Nov; 35(11):1278-1283. PubMed ID: 37773778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study.
    Lee H; Lee YH; Kim SU; Kim HC
    Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2138-2147.e10. PubMed ID: 33348045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of cardiovascular mortality between MAFLD and NAFLD: A cohort study.
    Yoo TK; Lee MY; Kim SH; Zheng MH; Targher G; Byrne CD; Sung KC
    Nutr Metab Cardiovasc Dis; 2023 May; 33(5):947-955. PubMed ID: 36746687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mortality outcomes in diabetic metabolic dysfunction-associated fatty liver disease: non-obese versus obese individuals.
    Zhang P; Zeng Y; Yang S; Ye C; Wang M; Peng T; Li L; Dong X
    Sci Rep; 2024 May; 14(1):11320. PubMed ID: 38760435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic steatosis, metabolic dysfunction and risk of mortality: findings from a multinational prospective cohort study.
    Mayén AL; Sabra M; Aglago EK; Perlemuter G; Voican C; Ramos I; Debras C; Blanco J; Viallon V; Ferrari P; Olsen A; Tjønneland A; Langmann F; Dahm CC; Rothwell J; Laouali N; Marques C; Schulze MB; Katzke V; Kaaks R; Palli D; Macciotta A; Panico S; Tumino R; Agnoli C; Farràs M; Molina-Montes E; Amiano P; Chirlaque MD; Castilla J; Werner M; Bodén S; Heath AK; Tsilidis K; Aune D; Weiderpass E; Freisling H; Gunter MJ; Jenab M
    BMC Med; 2024 Jun; 22(1):221. PubMed ID: 38825687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of metabolic syndrome and metabolic dysfunction-associated fatty liver disease on cardiovascular risk by the presence or absence of type 2 diabetes and according to sex.
    Matsubayashi Y; Fujihara K; Yamada-Harada M; Mitsuma Y; Sato T; Yaguchi Y; Osawa T; Yamamoto M; Kitazawa M; Yamada T; Kodama S; Sone H
    Cardiovasc Diabetol; 2022 Jun; 21(1):90. PubMed ID: 35655263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic associated fatty liver disease better identifying patients at risk of liver and cardiovascular complications.
    Cheng YM; Wang CC; Kao JH
    Hepatol Int; 2023 Apr; 17(2):350-356. PubMed ID: 36471232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.